Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH
In: Endocrine Connections, Jg. 7 (2018), Heft 1, S. 133-138
Online
academicJournal
Zugriff:
We present herein our 20-year experience of pubertal induction in apubertal older (median age 56 years; range 38.4–69.5) men with congenital hypogonadotrophic hypogonadism (n = 7) using a simple fixed-dose and fixed-interval intramuscular testosterone that we originally pioneered in relation to achieving virilisation of natal female transgender men. This regime was effective and well tolerated, resulting in complete virilisation by around 1 year after treatment initiation. No physical or psychological adverse effects were encountered in this group of potentially vulnerable individuals. There were no abnormal excursions of laboratory parameters and extended follow-up beyond the first year of treatment revealed remarkable improvements in bone density. We highlight advantages to both patients and physicians of this regime in testosterone-naïve older men with congenital hypogonadism and discourage the over-rigid application to such patients of treatment algorithms derived from paediatric practice in relation to the evaluation and management in younger teenagers with delayed puberty of uncertain cause.
Titel: |
Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH
|
---|---|
Autor/in / Beteiligte Person: | Pazderska, Agnieszka ; Mamoojee, Yaasir ; Artham, Satish ; Miller, Margaret ; Stephen G Ball ; Cheetham, Tim ; Quinton, Richard |
Link: | |
Zeitschrift: | Endocrine Connections, Jg. 7 (2018), Heft 1, S. 133-138 |
Veröffentlichung: | Bioscientifica, 2018 |
Medientyp: | academicJournal |
ISSN: | 2049-3614 (print) |
Schlagwort: |
|
Sonstiges: |
|